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Abstract
Objective
We aimed to investigate which clinical and metabolic tests offer optimal accuracy and
acceptability to help diagnose diabetes among a large sample of people with serious mental
illness in receipt of antipsychotic medication.
Methods
A prospective observational study design of biochemical and clinical factors was used. Bio-
chemical measures were fasting glucose, insulin and lipids, oral glucose tolerance testing
(OGTT), hemoglobin A1c, and insulin resistance assessed with the homeostatic model
(HOMA-IR) were determined in a consecutive cohort of 798 adult psychiatric inpatients
receiving antipsychotics. Clinical variables were gender, age, global assessment of func-
tioning (GAF), mental health clinicians’ global impression (CGI), duration of severe mental
illness, height, weight, BMI and waist/hip ratio. In addition, we calculated the risk using com-
bined clinical predictors using the Leicester Practice Risk Score (LPRS) and the Topics Dia-
betes Risk Score (TDRS). Diabetes was defined by older criteria (impaired fasting glucose
(IFG) or OGTT) as well as2010 criteria (IFG or OGTT or Glycated haemoglobin (HBA1c)) at
conventional cut-offs.
Results
Using the older criteria, 7.8% had diabetes (men: 6.3%; women: 10.3%). Using the new cri-
teria, 10.2% had diabetes (men: 8.2%, women: 13.2%), representing a 30.7% increase (p =
0.02) in the prevalence of diabetes. Regarding biochemical predictors, conventional OGTT,
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IFG, and HbA1c thresholds used to identify newly defined diabetes missed 25%, 50% and
75% of people with diabetes, respectively. The conventional HBA1c cut-point of�6.5% (48
mmol/mol) missed 7 of 10 newly defined cases of diabetes while a cut-point of�5.7%
improved sensitivity from 44.4% to up to 85%. Specific algorithm approaches offered rea-
sonable accuracy. Unfortunately no single clinical factor was able to accurately rule-in a
diagnosis of diabetes. Three clinical factors were able to rule-out diabetes with good accu-
racy namely: BMI, waist/hip ratio and height. A BMI < 30 had a 92% negative predictive
value in ruling-out diabetes. Of those not diabetic, 20% had a BMI� 30. However, for com-
plete diagnosis a specific biochemical protocol is still necessary.
Conclusions
Patients with SMI maintained on antipsychotic medication cannot be reliably screened for
diabetes using clinical variables alone. Accurate assessment requires a two-step algorithm
consisting of HBA1c�5.7% followed by both FG and OGTT which does not require all
patients to have OGTT and FG.
Introduction
A rising population rate of overweight and obesity has contributed to a global diabetes epi-
demic, with harmful effects on mortality and morbidity worldwide [1]. Diabetes afflicts an esti-
mated 382 million people and by 2035 this will rise to 592 million but many remain
undiagnosed [2]. Diabetes implies a significant abnormality in glucose homeostasis with per-
sistent hyperglycaemia. However, the exact definition of diabetes offered by expert committees
has varied over time. In 1997, diabetes was defined by either an impaired fasting glucose (IFG)
>125 mg/dL (�7.0 mol/L) or a two-hour oral glucose tolerance test (OGTT) >199 mg/dL
(>11 mmol/L). In 2010, Glycated haemoglobin (HBA1c) had been added to the qualifying cri-
teria, such that diabetes mellitus can now be defined by one of three of the following: elevated
fasting glucose (?7.0 mol/L), 2-hour OGTT (>11 mmol/L) or HBA1c (>6.4%; 46 mmol/mol)
[3].Usually the abnormal test is repeated unless there is “unequivocal hyperglycemia” [3,4].
The addition of HbA1c reflects its contribution as an independent risk of morbidity and mor-
tality [5]. Moreover, HBA1c is convenient, as it can be measured at any time of the day without
fasting. However, it is unclear whether HbA1c is as good as blood glucose for predicting diabe-
tes complications, such as retinopathy. Certainly, higher HBA1c is a risk for future diabetes. In
a systematic review of 16 cohort studies with a follow-up interval averaging 5.6 years (range:
2.8–12 years), those with an HBA1c between 6.0 to 6.5% (42 mmol/mol—48 mmol/mol) had a
5-year risk of diabetes of 25% to 50% [6]. HBA1c has a modest-to-strong correlation with IFG
and OGTT. For example, up to half of people with diabetes would not be diagnosed using
HbA1c, and half of those diagnosed using HbA1c would not currently be diagnosed using IFG
[7, 8]. The new definition of diabetes, which incorporates HBA1c, has increased the prevalence
of diabetes in all populations,[9] but has never previously been studied in patients with severe
mental illness (SMI), or those maintained on antipsychotic medications.
Observational studies have reported a clear association between patients with SMI and dia-
betes [10]. This is concerning as diabetes is associated with a reduced quality of life and
increased mortality in people with SMI [11].The risk appears particularly severe in those main-
tained on antipsychotics, notably most second-generation antipsychotics [12, 13]. The risk
An observational study diabetes screening in seriously mental ill patients receiving antipsychotic medication
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conferred by the illness and/or antipsychotics extends to other components of the metabolic
syndrome. For example, De Hert et al (2007) found that 27.8% of those started on second-gen-
eration antipsychotics had new (incident) metabolic syndrome (MetS) within three years,
compared to 9.8% of those treated with first-generation antipsychotic agents [14]. In studies
that have assessed metabolic abnormalities in drug-naïve, first-episode patients, some have
found impaired glucose tolerance or insulin resistance but others found no appreciable effect
and a recent meta-analysis found only modest abnormalities in metabolic syndrome or meta-
bolic risk factors in drug-naïve patients (exceptions may be smoking, fitness and diet)[15].
Therefore, it is assumed that antipsychotics indirectly worsen glucose regulation by promoting
obesity or directly by affecting glucose regulation through insulin resistance, [16] decreased
secretion of glucose-dependent insulinotropic polypeptide (GIP), increased glucagon secre-
tion, or by impairing beta cell function [17]. In addition, antipsychotics also contribute to dys-
lipidemia [18].
Despite these concerns about metabolic abnormalities in patients treated with antipsychot-
ics, only a few studies examined screening procedures for diabetes/prediabetes in this popula-
tion. In a modest sample of 100 patients, De Hert et al (2006) noted that a monitoring protocol
based only on fasting glucose would detect only 63.6% of patients with glucose abnormalities.
They suggested combining fasting glucose with fasting insulin [19]. This sample was later
expanded to 415 patients and testing procedures were re-examined [20]. Against an OGTT
definition of diabetes, IFG had a sensitivity of 46.2%, but a two-step procedure of impaired
fasting glucose >100mg/dl and then an OGTT only for patients positive in step 1 gave a sensi-
tivity of 96.2%, yet both retained 100% specificity. Manu et al (2012) used the new 2010 Ameri-
can Diabetes Association diagnostic criteria for prediabetes and found 37% of patients treated
with antipsychotics met criteria[21].Among patients with prediabetes, HBA1c (5.7–6.4 mmol/
mol) was the sole defining abnormality in 41%. Agarwal (2012) found that 48% of patients
with schizophrenia had high HBA1c levels� 5.7[22]. Only one study, however, has investi-
gated HBA1c in diagnosing diabetes. Hanssens et al (2006) reported a limited value of HBA1c
in diagnosing diabetes in those taking antipsychotics due to low sensitivity [23]. Since that
time, the definition of diabetes has been updated and research is required to identify the role
of HBA1c in diagnosing diabetes. Therefore we aimed to 1. fully examine the accuracy and
clinical utility of HBA1c and other markers of glucose regulation in the diagnosis of diabetes
in patients taking antipsychotics and 2. to develop an algorithm for clinicians to use in clinical
practice to detect diabetes in mental health populations.
Whilst the addition of non-fasting HBA1c simplifies the biochemical diagnosis of diabetes
in many non-specialist settings the diagnosis of diabetes remains a challenge due to the incon-
venience of biochemical testing. Necessity for biochemical tests reduces the acceptability and
uptake of testing for many clinicians and patients. The European evidence based guidelines for
the prevention of type 2 diabetes[24] and the International Diabetes Federation[25] have rec-
ommend the use of simple risk scoring systems to identify people at high risk of future diabe-
tes. However, these still rely on conventional testing. Recently, several groups have developed
and tested the accuracy of clinical variables to diagnose diabetes (and to a lesser extent pre-dia-
betes) without recourse to blood tests. These could be valuable in clinical practice if they were
sufficiently accurate. Usually these clinical variables have been combined in clinical prediction
algorithms or risk models [26, 27, 28, 29, 30, 31].Abbasi et al (2012) reviewed 12 such models
(an additional 13 required biochemical testing)[27]. Collins et al (2011) reviewed 43 risk pre-
diction models of which 17 were purely clinical [24]. Noble et al (2012) evaluated 94 risk pre-
diction models and identified 7 as being the most promising for adaptation and use in routine
clinical practice [26]. Risk models vary from simple to complex. The majority have been vali-
dated in North American or European study populations. It has been suggested that simple
An observational study diabetes screening in seriously mental ill patients receiving antipsychotic medication
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models, derived from clinical history alone could be useful in clinical practice and could
reduce the cost and inconvenience of screening. For example, the Diabetes Risk Calculator
derived from the National Health and Nutrition Examination Survey (NHANES) III [32]
includes questions about patient age, waist circumference, history of gestational diabetes,
height, race/ethnicity, hypertension, family history, and exercise. Other models include the
Atherosclerosis Risk in Communities (ARIC) risk calculator, the Australian Diabetes Risk
Assessment Tool (AusDrisk), the Cambridge Risk Score, FINDRISC and CANRISK (see
Table 1). Even clinical models vary in complexity of risk factors and scoring. Two particularly
simple models may be suitable for application in mental health settings. These are the Leicester
Practice Risk Score for Diabetes (LPRS) 33 and the Topics Diabetes Risk Score (TDRS) [34].
The accuracy of these clinical models is summarized in Table 1. One challenge of these models
is to yield high clinical utility in the face of a relatively low prevalence of diabetes, typically
3–6% in the general population. The value of such tools is that they can potentially be used as a
simpler form of screening which might increase the uptake of screening and ultimately reduce
the incidence or complications of type 2 diabetes [35, 36, 37].
Methods
Setting
In an observational study between November 2003 and July 2007, psychiatric patients were
asked by their treating psychiatrist to agree to a standardized battery of tests to identify MetS
and insulin resistance. All subjects gave written informed consent and the study was approved
by the University Psychiatric Center’s Ethics Committee KU Leuven campus, Kortenberg.
Clinical and laboratory measurements
The procedure included measurements of height, weight, body mass index (BMI), waist cir-
cumference, arterial blood pressure, fasting blood glucose, insulin and lipids, Glycated hemo-
globin (A1c), and a 2-hour oral glucose tolerance test (OGTT) after the ingestion of 75g of
glucose. As described previously, all tests were performed in the same laboratory and using the
same robust methods throughout the study period [13]. Fasting glucose, 2-hour postprandial
glucose during OGGT and HBA1c data were used to define diabetes mellitus according to new
and old (conventional) criteria. The older criteria were either a fasting glucose >125 mg/dl or
a 2-hour postprandial glucose >199 mg/dL. The new criteria are a fasting glucose >125 mg/dL
or a 2-hour postprandial glucose >199 mg/dLor an HBA1c�6.5% (48 mmol/mol); any of
which should be repeated unless there is unequivocal hyperglycaemia. In addition, in a patient
with classical symptoms of hyperglycaemia a random glucose >199 mg/dL is an acceptable
test. The fasting glucose and insulin data were used for the homeostatic model assessment of
insulin resistance (HOMA-IR) [38]. The weight and height were used to calculate the body
mass index (BMI). The waist circumference, arterial blood pressure, and fasting glucose, tri-
glycerides and high-density lipoprotein (HDL) cholesterol levels were also measured.
Psychiatric diagnoses were established according to DSM-IV by experienced psychiatrists
who were qualified and familiar with the management of psychiatric patients taking antipsy-
chotics. They were blinded to the study aims and affiliated with the University Psychiatric
Center and responsible for the patient’s treatment. The treating psychiatrists assessed the
severity of symptoms and rated them using the Global Assessment of Function (GAF) from 0
(worst) to 100 (best)[39] and the Clinical Global Impressions Severity (CGI-S) Scale from 1
(normal) to 7 (extremely ill)[40].
An observational study diabetes screening in seriously mental ill patients receiving antipsychotic medication
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Diabetes modelling
Of the many clinical models available we chose to examine two popular models: the Leicester
Practice Risk Score for Diabetes (LPRS) [30] and the Topics Diabetes Risk Score (TDRS) [31].
The LPRS encompasses the following risk factors: age, ethnicity, gender, first degree family his-
tory of diabetes, hypertension, waist circumference and BMI and has been validated in an
Table 1. Summary diabetic risk clinical models from general population studies.
Study Country Model Description Sensitivity Specificity Area
under
ROC
Sample
Size
Youden
Prospective (incident cases)
Aekplakorn et al (2006)
[65]
Thailand Thai Risk: Age, sex, BMI, abdominal obesity (waist
circumference), hypertension, family history of diabetes
77 61.9 0.75 2420 0.389
Balkau et al (2008) [66] France Men: waist circumference, smoking status, hypertension
Women: waist circumference, family history of diabetes,
hypertension.
50 74 66 3817 0.24
Gao et al (2009) [67] Mauritius Qingdao Score:Age, sex, BMI, waist circumference, family
history of diabetes
74.5 48.5 0.63 3094 0.23
Heianza et al (2013)
[34]
Japan TDRS: age, sex, family history of diabetes, current smoking habit,
BMI, and hypertension
72.7 68.1 0.77 33,335 0.408
Kahn et al (2009) [68] USA Diabetes family history, hypertension, ethnicity, age, smoking
status, waist circumference, height, resting pulse, weight
69 64 0.71 3142 0.33
Lindstro¨m et al (2003)
[69]
Finland FINDRISC: Age, BMI, waist circumference, use of blood
pressure medication, history of high blood glucose, physical
activity, daily consumption of vegetables
78 77 0.85 4,435 0.55
Robinson et al (2011)
[70]
Canada CANRISK: Age, BMI, waist circumference, use of blood pressure
medication, history of high blood glucose, physical activity, daily
consumption of vegetables
70 67 0.75 1676 0.37
Schulze et al (2007) [71] Germany German Diabetes Risk Score: Waist circumference, height, age,
hypertension, diet, alcohol consumption, physical activity,
former or current smoker
83 68 0.83 25,167 0.51
Cross-sectional (Prevalent Cases)
Al-Lawati et al (2007)
[72]
Oman Oman Diabetes Risk Score: Age, waist circumference, BMI,
family history of diabetes, hypertension
78.6 73.4 0.83 4881 0.52
Baan et al (1999) [73] The
Netherlands
Rotterdam Score: Age, sex, use of antihypertensive medication,
obesity (BMI� 30)
78 55 0.7 2364 0.33
Bang et al (2009) [74] USA Patient Self-Assessment Score: Age, sex, family history of
diabetes, history of hypertension, obesity (BMI or waist
circumference), physical activity
82 63 0.79 5258 0.45
Gao et al (2010) [75] China Chinese Risk Score: Age, waist circumference, family history of
diabetes
89 27 0.64 6322 0.16
Glu¨mer et al (2004)
[76]
Denmark Danish Risk Score: Age, BMI, sex, known hypertension, physical
activity, family history of diabetes
76 72 0.81 6,784 0.48
Gray et al (2010)
[Addition cohort] [33]
UK LPRS: age, ethnicity, sex, first degree family history of diabetes,
hypertension, waist circumference and BMI
81.1 41 0.69 6390 0.221
Gray et al (2010)
[Validation cohort]
[33]
UK LPRS: age, ethnicity, sex, first degree family history of diabetes,
hypertension, waist circumference and BMI
91.5 32.4 0.72 3171 0.239
Pires de Sousa et al
(2009)[77]
Brazil Brazilian Simple Prediction Model: Age, BMI, hypertension 76 67 0.77 1224 0.43
Ramachandran et al
(2005)[78]
India Age, family history of diabetes, BMI, waist circumference,
physical activity
76 59 0.73 10,003 0.35
Footer: Leicester Practice Risk Score (LPRS); Topics Diabetes Risk Score (TDRS); Finish Risk Score (FINDRISC), Canadian Risk Score (CANRISK)
https://doi.org/10.1371/journal.pone.0210674.t001
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ethnically diverse European population (sensitivity 91.5%, specificity 32.4, area under the
curve 0.72). The TDRS includes age, sex, family history of diabetes, current smoking habit,
BMI, and hypertension and has been validated in a Japanese sample and is currently the largest
study of its type (sensitivity 72.7%, specificity 68.1%, area under the curve 0.77). In addition to
these combination models, we examined the diagnostic accuracy of each individual clinical
risk factor.
Inclusion and exclusion criteria
We included psychiatric patients without diabetes at baseline consecutively admitted to a sin-
gle institution in Belgium. We excluded patient unable or unwilling to consent and those not
taking antipsychotic medication. Thus the study cohort comprised 820 patients but 22 were
excluded as they were not treated with antipsychotic drugs leaving 798 eligible patients. This
provided sufficient power to analyse at least 8 predictor variables. Patients were tested and
found to be free of diabetes prior to starting antipsychotics; therefore, the diabetes cases are
incident cases. Altogether, 49.1% were taking antipsychotics <3 months, 3.9% 3–6 months,
5.9% 6–9 months, and 41.1% more >1 year. The proportions of patients treated with the same
antipsychotic drug for more than 3 months were 81.4% for those receiving first-generation
drugs, 76.0% for clozapine, 56.6% for amisulpride, 46.2% for risperidone, 46.2% for olanza-
pine, 38.7% for quetiapine and 12.2% for aripiprazole.
Statistical analyses
A receiver operator characteristic (ROC) curve analysis was conducted equally weighted for
false positives and false negatives tested the best single markers for ruling-in (case-finding) or
ruling out (screening). We also examined sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), likelihood ratios and clinical utility index (CUI) and
relevant confidence intervals for all tests (all available from www.clinicalutlity.co.uk). In addi-
tion, we used ROC curve to calculate the optimal cut-off points for each test. For overall accu-
racy we used fraction correct (also known as overall accuracy = true positives plus true
negatives / all cases). In order to calculate clinical utility, we used the clinical utility index. The
CUI allows calculation of qualitative as well as quantitative value of a test [41, 42]. The clinical
utility index takes into account both discriminatory ability and occurrence for case-finding
(CUI+) and screening (CUI-) such that the positive utility index (CUI+) = sensitivity x positive
predictive value and the negative utility index (CUI-) = specificity x negative predictive value.
Further details are available here: www.clinicalutility.co.uk There commended qualitative
grades of diagnostic accuracy were applied according to previous publications [43]. Namely
the grades of the clinical utility index were> = 0.81: excellent, > = 0.64: good and> = 0.49:
fair > = 0.36: poor; <0.36: very poor. Finally, algorithm approaches were investigated. Algo-
rithm approaches attempt to improve upon acceptability / test burden. They usually start with
a simple test, acceptability to the population as a whole (such as the HBA1c) and then advise a
fasting test, or OGTT only if needed.
Results
Demographic and psychiatric characteristics
The total sample comprised 798 patients taking antipsychotic medications with a mean age of
37.7years. 61.1% were male and the most common diagnosis was schizophrenia (67.2%). 62%
were smokers. Full details of demographic and psychiatric characteristics are presented in
Table 2.
An observational study diabetes screening in seriously mental ill patients receiving antipsychotic medication
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Prevalence of diabetes and characteristics
Using the old definition of diabetes incorporating IFG and OGTT, 62/798 (7.8%) had diabetes.
The rate was 30/474 (6.3%) in men and 32/311 (10.3%) in women (Chi2 = 4.0, p = 0.04). Using
a definition of diabetes, incorporating IFG, OGTT and HBA1c, 81/798 (10.2%) had diabetes;
8.2% in men and 13.2% in women (Chi2 = 5.3, p = 0.02). Compared to the non-diabetic group
(n = 717, 62.5% male), there was a lower percentage of men in both the old (43.5%) and new
definitions (49.4%). In addition, the patients in the old and new diabetes criteria both had
higher BMI (29.7 and 29.4 respectively) than the non-diabetic patient group (26.1). There was
a higher percentage of people with depression and bipolar disorder in the old and new diabetes
criteria compared to the non-diabetic group but a higher percentage of people with schizo-
phrenia in the non-diabetic group. Of 536 patients diagnosed with schizophrenia, diabetes was
present in 6.3% (old definition) and 8.4% (new definition). The Cohen’s kappa agreement
between the two definitions was 0.86 (95% CI = 0.78 to 0.93). The general European popula-
tion rate of diabetes is approximately 3.3% (old definition) and 6.8% (new definition), but the
patient group reported here has a significantly younger mean age.7 Correcting for this, the
Table 2. Demographic and psychiatric characteristics.
Total Sample
(n = 798)
New Definition of Diabetes
(n = 80)
No Diabetes(n = 718)
Age (years) 37.7 47.0 36.7
Male Gender 61.1% 49.4% 62.5%
Duration (years) 11.1 16.7 10.5
Schizophrenia 67.2% 45.6% 68.5%
Bipolar 14.3% 17% 13.9%
Depression 2.4% 7% 2%
GAF (mode) 55 60 55
CGI 4 4 4
Weight 79.3kg 85.0kg 78.6kg
BMI 26.4 29.4 26.1
Smokers 62% 66.7% 61.6%
https://doi.org/10.1371/journal.pone.0210674.t002
Fig 1. Prevalence rate of diabetes and prediabetes by age in women taking antipsychotics (n = 310).
https://doi.org/10.1371/journal.pone.0210674.g001
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expected population rate would be 1.1% (old definition) and 1.4% (new definition) suggesting
a relative risk of 7.1 and 7.3, respectively.
Particularly high rates of diabetes were seen in some subgroups. The rate of old and newly
defined diabetes in those taking antipsychotic drugs less than 3 months was 8.9% and 7.9%,
3–6 months 12.9% and 12.9%, 6–9 months 21.3% and 6.3%, and>1 year 10.4% and 13.1%,
respectively. However, the highest rates related to age. In males and females aged 45–55 years
old, diabetes was present in 14.1 and 14.3%, respectively, and in those aged 56–64, diabetes
was present in 32.1% and 28.9% respectively (Figs 1 and 2).
Glucose metabolism measurements
Mean cholesterol, trigyceride, HDL and LDL levels were 216 mg/dL, 229 mg/dL, 48 mg/dL,
124 mg/dL in the cohort of patients with diabetes using the old definition and 213 mg/dL, 211
mg/dL, 48 mg/dL and 124 mg/dL using the new definition. Using the old and new definitions
of diabetes mean fasting glucose was 125.1 mg/dL vs. 117.4 mg/dL, mean fasting insulin was
20.9 mIU/Lvs. 20.1 mIU/L and mean HOMA-IR was 6.8 vs. 6.2, respectively. In short, the old
definition of diabetes identified a more strongly at risk cohort according to their biochemical
profile but the new definition identified a larger cohort at risk.
Predictive accuracy of clinical variables in the diagnosis of diabetes
The performance of each individual clinical variable against biochemically defined diabetes is
shown in Table 3. No clinical variable was particularly accurate. Judging by area under the
curve, the most accurate variable was age (ROC = 0.742), followed by BMI (ROC = 0.653) and
illness duration (ROC = 0.639). Judging by overall correct (defined as true positives + true neg-
atives / all cases) the most accurate were BMI (76.6% correct), waist/hip ratio (74.2% correct)
and height (68.7% correct). Rule-in and rule-out accuracy may be best considered separately.
The optimal individual clinical variables to confirm (rule-in with minimal false positives) a
diagnosis of diabetes were 1.) age and 2.) illness duration. However, no variable performed
well, all were very poor at confirming a correct diagnosis. The optimal individual clinical vari-
ables to refute (rule-out with minimal false negatives) a diagnosis of diabetes were 1.) BMI 2.)
waist/hip ratio and 3.) height. These three variables all performed well in this capacity and
could be considered as initial screening questions to rule out people unlikely to have diabetes.
For example, a BMI less than 30 would correctly identify non- diabetic patients with SMI with
Fig 2. Prevalence rate of diabetes and prediabetes by age in men taking antipsychotics (n = 488).
https://doi.org/10.1371/journal.pone.0210674.g002
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92.5% accuracy (NPV) with 7.5% false negative rate. Of those non- diabetic patients with SMI
80% had a low BMI, but 20% had a high BMI despite being non-diabetic. However, a high
BMI could not confirm a diagnosis. Only 45% of those with diabetes had a high BMI and of all
patients with a high BMI, only 21.3% would actually be diabetic (PPV).
Predictive accuracy of clinical models in the diagnosis of diabetes
The performance of combined clinical variables in the Leicester Practice Risk Score (LPRS)
and the Topics Diabetes Risk Score (TDRS) were evaluated against biochemically defined
Table 3. Clinical factors in the diagnosis of diabetes in patients receiving antipsychotic medication.
Sensitivity Specificity PPV NPV Clinical
Utility (+)
Clinical
Utility (-)
Overall
Correct
AUC Optimal Cut-
Off�
LR(+) LR
-
Symptom (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95%
CI)
(95%
CI)
Individual Clinical
Risk Factors
Gender 54.0%
(43.6%-
64.5%)
62.3%
(58.8%-
65.9%)
14.6%
(10.4%-
18.7%)
92.0%
(89.6%-
94.3%)
Very poor
(0.079,
0.076–0.081)
Fair
(0.573,
0.572–0.574)
61.46 0.581
(0.526 to
0.637)
2 1.43
(1.16–
178)
0.74
(0.58–
0.93)
Age 80.5%
(72.1%-
88.8%)
58.7%
(55.1%-
62.2%)
18.8%
(14.4%-
23.2%)
96.2%
(94.4%-
98.0%)
Very poor
(0.151,
0.148–0.154)
Fair
(0.564,
0.563–0.565)
60.98 0.742
(0.689 to
0.794)
38.9 1.95
(1.70–
2.23)
0.33
(0.22–
0.51)
Mental health GAF 87.4%
(80.4% -
94.3%)
20.2%
(17.3%-
23.1%)
11.5%
(8.9%-
14.1%)
93.1%
(89.1%-
97.0%)
Very poor
(0.100,
0.099–0.102)
Very poor
(0.188,
0.186–0.189)
27.32 0.504
(0.445 to
0.562)
45 1.09
(1.00–
1.20)
0.63
(0.35–
1.11)
Mental health CGI 93.1%
(87.8%-
98.4%)
13.0%
(10.5%-
15.4%)
11.3%
(8.8%-
13.7%)
94.1%
(89.4%-
98.7%)
Very poor
(0.105,
0.103–0.106)
Very poor
(0.122,
0.120–0.123)
21.46 0.508
(0.450 to
0.565)
5 1.07
(1.00–
1.14)
0.53
(0.24–
1.18)
SMI Duration
Illness
72.4%
(63.0%-
81.8%)
56.9%
(53.3%-
60.5%)
16.6%
(12.5%-
20.7%)
94.6%
(92.4%-
96.7%)
Very poor
(0.120,
0.118–0.123)
Fair
(0.538,
0.537–0.539)
58.54 0.639
(0.571 to
0.706)
9.4 1.68
(1.44–
1.96)
0.48
(0.34–
0.69)
Height 49.4%
(38.9%-
59.9%)
70.9%
(67.7%-
74.2%)
16.8%
(11.8%-
21.8%)
92.2%
(90.0%-
94.4%)
Very poor
(0.083,
0.080–0.086)
Good
(0.654,
0.653–0.655)
68.66 0.621
(0.539 to
0.703)
1.68 1.70
(1.34–
2.16)
0.71
(0.58–
0.88)
Weight 71.3%
(61.8%-
80.8%)
42.0%
(38.4%-
45.6%)
12.7%
(9.6%-
15.9%)
92.5%
(89.7%-
95.3%)
Very poor
(0.091,
0.089–0.093(
Poor
(0.389,
0.387–0.390)
45.12 0.575
(0.511 to
0.639)
74.2 1.23
(1.06–
1.42)
0.68
(0.49–
0.96)
BMI 44.8%
(34.4%-
55.3%)
80.4%
(77.5%-
83.2%)
21.3%
(14.6%-
28.0%)
92.5%
(90.4%-
94.5%)
Very poor
(0.096,
0.091–0.100)
Good
(0.743,
0.742–0.744)
76.59 0.653
(0.590 to
0.716)
29.6 2.28
(1.73–
3.00)
0.69
(0.57–
0.83)
Waist/Hip Ratio 39.1%
(28.8%-
49.3%)
78.3%
(75.3%-
81.3%)
17.6%
(11.7%-
23.5%)
91.5%
(89.4%-
93.7%)
Very poor
(0.069,
0.065–0.072)
Good
(0.717,
0.716–0.718)
74.15 0.594
(0.528 to
0.661)
1 1.80
(1.34–
2.42)
0.78
(0.65–
0.92)
Combined Factors
(Models)
Leicester Practice
Risk Score (LPRS)
[cut off� 14]
74.1%
(64.5%-
83.6%)
64.2%
(60.6%-
67.7%)
18.9%
(14.1%-
23.7%)
95.6%
(93.8%-
97.5%)
Very poor
(0.140,
0.137–0.145)
Fair
(0.614,
0.613–0.615)
65.16 0.756
(0.705 to
0.807)
14 2.07
(1.76–
2.43)
0.40
(0.28–
0.59)
TOPICS Model
(TDRS)
[cut off� 8]
71.6%
(61.8%-
81.4%)
67.2%
(63.8%-
70.7%)
19.8%
(14.7%-
24.9%)
95.4%
(93.6%-
97.3%)
Very poor
(0.142;
0.138–0.145)
Good
(0.643,
0.641–0.643)
67.67 0.765
(0.712 to
0.817)
8 2.18
(1.84–
2.60)
0.42
(0.30–
0.60)
Footnote: AUC- Area under receiver operator characteristic curve; PPV–Positive predictive value; NPV—Negative predictive value; UI = Clinical utility index. The
positive clinical utility index (UI+ = sensitivity x PPV) measures rule-in value and the negative clinical utility index (UI- = specificity x NPV) measures rule-out value.
The following qualitative grades of diagnostic accuracy have been applied to the clinical utility index were > = 0.81: excellent, <0.81 good > = 0.64; <0.64 fair> = 0.49;
<0.49 poor. > = 0.36; <0.36 very poor
https://doi.org/10.1371/journal.pone.0210674.t003
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diabetes (Table 4). These clinical models were not particularly accurate but they were no less
accurate than shown in their parent (non-SMI) studies (Table 1). Judging by area under the
curve and by overall correct, the most accurate model was TDRS followed by LPRS. When
rule-in and rule-out accuracy were considered separately, the optimal model to refute (rule-
out with minimal false negatives) a diagnosis of diabetes was TDRS. When negative at a score
of<8, TDRS had 95.4% negative predictive value, meaning only about 5% with a low score
would be missed (false negatives). Although neither clinical model was satisfactory at confirm-
ing a diagnosis, either could be used as an initial screening model in order to rule out people
unlikely to have diabetes. There was one limitation of this approach, TDRS and LPRS would
only be negative (under threshold) in 67% and 64% of non-diabetic patients respectively. In
this respect these combination models perform significantly worse than just considering BMI
alone. A low BMI was almost as accurate as a low score on TDRS (92.5% vs 95.4%) but with
the advantage that 80% of non-diabetic patients would have a relevant negative (under thresh-
old) score compared with 67% for the TDRS. Thus, we conclude that these clinical prediction
models have little if any advantage over the individual clinical variables used alone. For com-
pleteness, we finally examined the accuracy of the clinical models to identify either pre-diabe-
tes or diabetes. Accuracy was inferior when identifying both pre-diabetes and diabetes
compared with diabetes alone. For either pre-diabetes or diabetes the AUC for TDRS was
0.661 (CI = 0.624 to 0.699) compared with 0.765 (CI = 0.712 to 0.817) for diabetes alone. For
either pre-diabetes or diabetes the AUC for LPRS was 0.647 (CI = 0.609 to 0.685) compared
with 0.756 (CI = 0.705 to 0.807) for diabetes alone. This confirms that these models were not
particularly suitable for the identification of pre-diabetes or diabetes in SMI.
Predictive accuracy of HBA1c and related variables for Pre2010 diabetes
definition
Single metabolic tests. The performance of metabolic biochemical markers against the
pre-2010 (conventional) definition of diabetes is shown in Table 2 and Fig 3. After choosing
the optimal cut, no test was satisfactory for confirming diabetes. The best single test that could
be used to confirm a diagnosis of diabetes with minimal false positives was the two-hour
OGTT which had a positive predictive value (PPV) of 46%. All tests performed better in a rule-
out capacity, which excludes those without a diagnosis of diabetes with minimal false nega-
tives. All tests had a negative predictive value (NPV) above 95%, but the one-hour response to
OGTT and fasting glucose (at a cut-point of 98mg/dl) both had NPV’s above 99%. However,
both these tests suffered from a relative lack of specificity. When seeking the optimal rule-out
test, the discrimination and occurrence of a negative test in those without the condition should
be considered equally. With this in mind, the optimal rule-out test was the two-hour OGTT
result, followed by HOMA-IR, fasting glucose level and one-hour OGTT. HBA1c offered a
very poor confirmation of diabetes with only 19% PPV, but it could be used as part of a screen-
ing algorithm (see below), as it possessed 97.8% NPV.
Single metabolic tests (Apriori thresholds). Using conventional cut-offs proposed for
the diagnosis of diabetes in the general population revealed some unexpected findings. Con-
ventional cut-offs in HBA1c, fasting glucose or OGTT all produced excellent rule-out statistics
with few false negatives, suitable for use as an initial screening step. However, only two-hour
OGTT (at >199mg/dl) was satisfactory for case-finding of diabetes. Even in this case, only 3 in
4 of subjects with diabetes had an OGTT >199mg/dl; 1 in 4 would be missed (sensitivity was
74%). HBA1c at the conventional cut-point of�6.5 proved wholly unsatisfactory as a method
of confirming (older) diabetes. Only about 1 in 4 with diabetes would score positive on HBA1c
at a cut-point of 6.5% (48 mmol/mol), 3 in 4 being missed.
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Table 4. Optimal biochemical measure vs old definition of diabetes.
Sensitivity Specificity PPV NPV Clinical
Utility (+)
Clinical
Utility (-)
Overall
Correct
AUC Optimal Cut-
Off�
LR(+) LR
-
symptom (95% CI) (95% CI) (95%
CI)
(95%
CI)
(95% CI) (95% CI) (95%
CI)
(95%
CI)
HBA1C 80.6%
(70.8–
90.5)
71.3%
(68.1–
74.6)
19.2%
(13.9–
24.5)
97.8%
(96.5–
99.0)
Very Poor
0.154
(0.150–
0.159)
Good
0.697
(0.697–
0.698)
72.06 0.832
(0.778–
0.887)
5.8 2.81 0.27
(0.16–
0.45)
Fasting Glucose 91.9%
(85.5–
98.7)
82.5%
(79.7–
85.2)
30.6%
(22.7–
38.6)
99.2%
(98.5–
99.9)
Very Poor
0.282
(0.267–
0.288)
Excellent
0.818
(0.818–
0.818)
83.21 0.935
(0.894–
0.975)
98 mg/dl 5.25 0.10
(0.04–
0.23)
OGTT 30min 85.5%
(76.7–
94.3)
76.7%
(73.6–
79.8)
24.0%
(17.5–
30.4)
98.4%
(97.4–
99.4)
Very Poor
0.205
(0.200–
0.210)
Good
0.755
(0.754–
0.755)
77.39 0.867
(0.817–
0.918)
179 mg/dl 3.67 0.19
(0.10–
0.35)
OGTT 60min 91.9%
(85.2–
98.7)
83.5%
(80.8–
86.2)
32.4%
(24.0–
40.8)
99.2%
(98.5–
99.9)
Very Poor
0.298
(0.291–
0.304)
Excellent
0.828
(0.828–
0.829)
84.16 0.936
(0.900–
0.971)
181 mg/dl 1.10 0.10
(0.04–
0.22)
OGTT 120min 88.7%
(80.8–
96.6)
91.1%
(89.0–
93.2)
46.2%
(34.1–
58.4)
98.9%
(98.2–
99.7)
Poor
0.410
(0.402–
0.418)
Excellent
0.902
(0.901–
0.902)
90.93 0.947329
(0.908–
0.986)
145 mg/dl 0.97 0.12
(0.06–
0.25)
Fasting Insulin 56.5%
(44.1–
68.8)
81.9%
(79.1–
84.7)
20.8%
(13.9–
27.7)
95.7%
(94.1–
97.3)
Very Poor
0.118
(0.112–
0.123)
Good
0.784
(0.784–
0.785)
79.95 0.722
(0.645–
0.799)
14.7 3.12 0.53
(0.40–
0.71)
HOMA-IR 66.1%
(54.3–
77.9)
86.7%
(84.2–
89.1)
29.5%
20.5–
38.5)
96.8%
(95.5–
98.2)
Very Poor
0.195
(0.188–
0.202)
Excellent
0.839
(0.839–
0.840)
85.09 0.800
(0.733–
0.866)
3.38 4.97 0.39
(0.28–
0.55)
Apriori Thresholds
HBA1C�6.5 27.4%
(16.3–
38.5)
97.4%
(96.3–
98.6)
47.2
(24.2–
69.6)
94.1%
(92.4–
97.2)
Very Poor
0.129
(0.117–
0.142)
Excellent
0.917
(0.916–
0.917)
91.98 0.624
(0.568–
0.680)
�6.5 N/A 0.75
(0.64–
0.87)
Fasting Glucose >125mg/
dl
48.4%
(35.9–
60.8)
100.0%
(100–100)
100.0%
(100–
100)
95.8%
(94.4–
97.2)
Poor
0.484
(0.469–
0.499)
Excellent
0.958
(0.958–
0.958)
95.99 0.742
(0.679–
0.804)
>125mg/dl N/A 0.52
(0.41–
0.66)
OGTT 120min�199mg/dl 74.2%
(63.3–
85.1)
100.0%
(100–100)
100.0%
(100–
100)
97.9%
(96.8–
98.9)
Good
0.742
(0.734–
0.750)
Excellent
0.979
(0.979–
0.979)
97.99 0.871
(0.816–
0.925)
�199mg/dl N/A 0.26
(0.17–
0.39)
Algorithm Approaches
Van Winkel (FG then
OGTT)
59.7%
(47.5–
71.9)
100.0%
(100–100)
100.0%
(100–
100)
96.7%
(95.4–
98.0)
Fair
0.597
(0.584–
0.609)
Excellent
0.967
(0.967–
0.967)
96.87 0.798
(0.736–
0.860)
As per
algorithm
N/A 0.40
(0.30–
0.55)
Mitchell(a) (HBA1c > FG
AND OGTT)
71.0%
(59.7–
82.3)
100.0%
(100–100)
100.0%
(100–
100)
97.6%
(96.5–
98.7)
Good
0.710
(0.701–
0.719)
Excellent
0.976
(0.976–
0.976)
97.74 0.855
(0.798–
0.911)
As per
algorithm
N/A 0.29
(0.20–
0.43)
Mitchell(b)
(HBA1c > OGTT)
54.8%
(42.5–
67.2)
100.0%
(100–100)
100.0%
(100–
100)
96.3%
(95.0–
97.7)
Fair
0.548
(0.535–
0.562)
Excellent
0.963
(0.963–
0.963)
96.49 0.774
(0.712–
0.837)
As per
algorithm
N/A 0.45
(0.34–
0.59)
(Continued)
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Algorithm approaches. Regarding aim 2 of the study, we investigated seven algorithm
approaches to the diagnosis of diabetes. The algorithm proposed by van Winkel [20], namely a
Table 4. (Continued)
Sensitivity Specificity PPV NPV Clinical
Utility (+)
Clinical
Utility (-)
Overall
Correct
AUC Optimal Cut-
Off�
LR(+) LR
-
Mitchell(c) (HBA1c> FG) 33.9%
(22.1–
45.7)
100.0%
(100–100)
100.0%
(100–
100)
94.7%
(93.2–
96.3)
Very Poor
0.339
(0.321–
0.357)
Excellent
0.947
(0.947–
0.947)
94.86 0.669
(0.610–
0.729)
As per
algorithm
N/A 0.66
(0.55–
0.79)
Mitchell(d)(HBA1c > FG
or OGTT)
45.2%
(32.8–
57.5)
100.0%
(100–100)
100.0%
(100–
100)
95.6%
(94.1–
97.0)
Poor
0.453
(0.436–0.468
Excellent
0.956
(0.956–
0.956)
95.74 0.589
(0.541–
0.637)
As per
algorithm
N/A 0.55
(0.44–
0.69)
Mitchell(e)(HBA1c5.8
>ALL)
71.0%
(59.7–
82.3)
100.0%
(100–100)
100.0%
(100–
100)
97.6%
(96.4–
98.7)
Good
0.710
(0.701–
0.719)
Excellent
0.976
(0.975–
0.976)
97.69 0.854
(0.798–
0.912)
As per
algorithm
N/A 0.29
(0.20–
0.43)
Mitchell(f)(HBA1c5.7
>ALL)
80.6%
(70.8–
90.5)
100.0%
(100–100)
100.0%
(100–
100)
98.4%
(97.5–
99.3)
Good
0.806
(0.800–
0.813)
Excellent
0.984
(0.984–
0.984)
98.5 0.903
(0.854 to
0.953)
As per
algorithm
N/A 0.19
(0.12–
0.32)
Footnote: AUC- Area under receiver operator characteristic curve; PPV–Positive predictive value; NPV—Negative predictive value; UI = Clinical utility index. The
positive clinical utility index (UI+ = sensitivity x PPV) measures rule-in value and the negative clinical utility index (UI- = specificity x NPV) measures rule-out value.
The following qualitative grades of diagnostic accuracy have been applied to the clinical utility index were > = 0.81: excellent, > = 0.64: good and > = 0.49: fair
<0.49 = poor.OGTT–oral glucose tolerance test. Algorithm approaches are as follows:Van Winkel (FG >100mg/dl then OGTT?199mg/dl); Mitchell(a) (HBA1c >5.8
then IFG AND OGTT); Mitchell(b) (HBA1c >5.8 then OGTT); Mitchell(c) (HBA1c >5.8 then IFG); Mitchell(d) (HBA1c >5.8 then IFG or OGTT); Mitchell(e) (HBA1c
>5.8 then IFG and OGTT and HBA1c)
https://doi.org/10.1371/journal.pone.0210674.t004
Fig 3. ROC curve of metabolic measures vs old definition of diabetes.
https://doi.org/10.1371/journal.pone.0210674.g003
An observational study diabetes screening in seriously mental ill patients receiving antipsychotic medication
PLOS ONE | https://doi.org/10.1371/journal.pone.0210674 September 12, 2019 12 / 23
fasting glucose >100mg/dl followed by a conventional OGTT for patients positive in step 1,
gave 100% specificity and PPV and very good NPV (96.7%) suggesting a potentially useful
approach. Its main limitation was the sensitivity of only 59.7% meaning 4 in 10 people with
diabetes would potentially be missed. A more convenient screening algorithm “Mitchell (b)”
consisting of (HBA1c >5.8% then OGTT) offered almost identical accuracy as the van Winkel
proposal, but without requiring an initially fasting sample. “Mitchell (b)” would necessitate
OGTT in only 25% of patients. The van Winkel algorithm would require a fasting sample on
everyone, but OGTT in only 20% of patients [20]. The only approaches that offered good or
better clinical utility were an initial HBA1c at a lower threshold (�5.9 or�5.7) followed by
conventional diabetes testing with the addition of IFG and OGTT. For maximum accuracy,
this protocol requires patients initially screening positive to have IFG and OGTT as well as
reinterpretation of HBA1c�6.5. At a HBA1c cut-off of�5.9, this protocol achieves 97.7%
overall accuracy, but only requires OGTT and fasting glucose in 25% of the sample, and at a
cut-off of�5.7 this protocol achieves 98.5% overall accuracy and only requires OGTT and fast-
ing glucose in 32.7% of the sample as opposed to 100% testing of all three measures to achieve
100% accuracy. The latter strategy achieves 80.6% sensitivity and 100% specificity.
Predictive accuracy of biochemical variables for detecting diabetes (2010
Diabetes definition)
Single metabolic tests. The performance of metabolic biochemical markers against a
close adaption of the 2010 definition of diabetes is shown in Table 5 and Fig 4. All tests were
Table 5. Optimal metabolic measure vs new definition of diabetes.
Symptom Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95%
CI)
NPV
(95%
CI)
Clinical
Utility (+)
(95% CI)
Clinical
Utility (-)
(95% CI)
Overall
Correct
AUC
(95% CI)
Optimal /
Preselected Cut-
Off�
LR
+(95%
CI)
LR-
(95%
CI)
Single Metabolic Tests
HBA1C 77.8%
(68.7–86.8)
80.9%
(78.0–83.8)
31.5%
(23.7–
39.3)
97.0%
(95.6–
98.4)
Very Poor
0.245
(0.240–
0.250)
Good
0.785
(0.784–
0.785)
80.58 0.885
(0.841–
0.930)
5.8 4.07
(3.37–
4.92)
0.27
(0.18–
0.41)
Fasting Glucose 77.8%
(68.7–86.8)
82.8%
(80.1–85.6)
33.9%
(25.5–
42.4)
97.1%
(95.7–
98.4)
Very Poor
0.263
(0.258–
0.269)
Good
0.804
(0.804–
0.805)
82.33 0.849
(0.791–
0.907)
98 mg/dl 4.53
(3.72–
5.53)
0.27
(0.18–
0.40)
OGTT 30min 72.5%
(62.7 = 82.3)
80.2%
(77.3–83.2)
29.4%
(21.9–
37.0)
96.2%
(94.7–
97.8)
Very Poor
0.213
(0.208–
0.219)
Good
0.772
(0.772–
0.773)
79.44 0.814
(0.759–
0.870)
179 mg/dl 3.67
(3.00–
4.48)
0.34
(0.24–
0.49)
OGTT 60min 80.0%
(71.2–88.8)
84.1%
(81.4–86.8)
36.4%
(27.5–
45.2)
97.4%
(96.1–
98.6)
Very Poor
0.291
(0.285–
0.297)
Excellent
0.819
(0.818–
0.819)
83.65 0.869
(0.819–
0.919)
181 mg/dl 5.02
(4.10–
6.15)
0.24
(0.15–
0.37)
OGTT 120min 75.0%
(65.5–84.5)
91.6%
(89.6–93.7)
50.4%
(37.7–
63.1)
97.0%
(95.7–
98.3)
Poor
0.378
(0.371–
0.386)
Excellent
0.888
(0.888–
0.889)
89.91 0.870
(0.816–
0.923)
145 mg/dl 8.94
(6.79–
1.77)
0.27
(0.19–
0.40)
Fasting Insulin 51.9%
(41.0–62.7)
82.4%
(79.6–85.2)
25.0%
(17.5–
32.5)
93.8%
(91.9–
95.7)
Very Poor
0.130
(0.125–
0.135)
Good
0.773
(0.773–
0.774)
79.32 0.685
(0.614–
0.755)
14.7 2.95
(2.27–
3.84)
0.58
(0.46–
0.73)
(Continued)
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Table 5. (Continued)
Symptom Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95%
CI)
NPV
(95%
CI)
Clinical
Utility (+)
(95% CI)
Clinical
Utility (-)
(95% CI)
Overall
Correct
AUC
(95% CI)
Optimal /
Preselected Cut-
Off�
LR
+(95%
CI)
LR-
(95%
CI)
HOMA-IR 60.5%
(49.8–71.1)
82.7%
(79.9–85.5)
28.3%
(20.4–
36.2)
94.9%
(93.2–
96.6)
Very Poor
0.171
(0.166–
0.177)
Good
0.785
(0.784–
0.785)
80.45 0.748
(0.683–
0.813)
3.38 3.50
(2.76–
4.44)
0.48
(0.36–
0.63)
Apriori Thresholds
HBA1C�6.5 44.4%
(33.6–55.3)
100.0%
(100–100)
100.0%
(100–
100)
94.1%
(92.4–
95.8)
Poor
0.444
(0.432–
0.457)
Excellent
0.941
(0.941–
0.941)
94.36 0.722
(0.667–
0.776)
�6.5 N/A 0.56
(0.46–
0.68)
Fasting Glucose
>125mg/dl
37.0%
(26.5–47.6)
100.0%
(100–100)
100.0%
(100–
100)
93.4%
(91.6–
95.1)
Poor
0.370
(0.357–
0.384)
Excellent
0.934
(0.933–
0.934)
93.61 0.685
(0.632–
0.738)
>125mg/dl N/A 0.63
(0.53–
0.74)
OGTT 120min
�199mg/dl
56.8%
(46.0–67.6)
100.0%
(100–100)
100.0%
(100–
100)
95.3%
(93.8–
96.8)
Fair
0.568
(0.558–
0.578)
Excellent
0.953
(0.953–
0.954)
95.61 0.784
(0.730–
0.838)
�199mg/dl N/A 0.43
(0.34–
0.55)
Algorithm Approaches
Van Winkel (FG then
OGTT)
45.7%
(34.8–56.5)
100.0%
(100–100)
100.0%
(100–
100)
94.2%
(92.6–
95.9)
Poor
0.457
(0.445–
0.469)
Excellent
0.942
(0.942–
0.942)
94.49 0.728
(0.717–
0.826)
As per
algorithm
N/A 0.54
(0.44–
0.66)
Mitchell(a)
(HBA1c > FG AND
OGTT)
54.3%
(43.5–65.2)
100.0%
(100–100)
100.0%
(100–
100)
95.1%
(93.6–
96.6)
Fair
0.543
(0.533–
0.554)
Excellent
0.951
(0.951–
0.951)
95.36 0.772
(0.717–
0.826)
As per
algorithm
N/A 0.46
(0.36–
0.58)
Mitchell(b)
(HBA1c > OGTT)
42.0%
(31.2–52.7)
100.0%
(100–100)
100.0%
(100–
100)
93.8%
(92.1–
95.6)
Poor
0.420
(0.407–
0.433)
Excellent
0.938
(0.938–
0.939)
94.11 0.710
(0.656–
0.764)
As per
algorithm
N/A 0.58
(0.48–
0.70)
Mitchell(c) (HBA1c>
FG)
25.9%
(16.4–35.5)
100.0%
(100–100)
100.0%
(100–
100)
92.3%
(90.4–
94.2)
Very Poor
0.259
(0.245–
0.274)
Excellent
0.923
(0.923–
0.923)
92.48 0.629
(0.582–
0.678)
As per
algorithm
N/A 0.74
(0.65–
1.18)
Mitchell(d)
(HBA1c > FG or
OGTT)
34.6%
(24.2–44.9)
100.0%
(100–100)
100.0%
(100–
100)
93.1%
(91.3–
94.9)
Very Poor
0.346
(0.332–
0.360)
Excellent
0.931
(0.931–
0.931)
93.36 0.568
(0.530–
0.605)
As per
algorithm
N/A 0.65
(0.56–
0.77)
Mitchell(e)
(HBA1c5.8>ALL)
77.8%
(68.7–86.8)
100.0%
(100–100)
100.0%
(100–
100)
97.6%
(96.4–
98.7)
Good
0.778
(0.772–
0.783)
Excellent
0.976
(0.975–
0.976)
97.74 0.889
(0.843–
0.934)
As per
algorithm
N/A 0.22
(0.15–
0.33)
Mitchell(f)(HBA1c5.7
>ALL)
85.2%
(77.4–92.9)
100.0%
(100–100)
100.0%
(100–
100)
97.6%
(96.4–
98.7)
Excellent
0.852
(0.848–
0.855)
Excellent
0.984
(0.983–
0.984)
98.50 0.925
(0.887 to
0.965)
As per
algorithm
N/A 0.15
(0.09–
0.25)
Footnote: AUC- Area under receiver operator characteristic curve; PPV–Positive predictive value; NPV—Negative predictive value; UI = Clinical utility index. The
positive clinical utility index (UI+ = sensitivity x PPV) measures rule-in value and the negative clinical utility index (UI- = specificity x NPV) measures rule-out value.
The following qualitative grades of diagnostic accuracy have been applied to the clinical utility index were > = 0.81: excellent, > = 0.64: good and > = 0.49: fair
<0.49 = poor.OGTT–oral glucose tolerance test. Algorithm approaches are as follows: Van Winkel (FG >100mg/dl then OGTT?199mg/dl); Mitchell(a) (HBA1c >5.8
then IFG AND OGTT); Mitchell(b) (HBA1c >5.8 then OGTT); Mitchell(c) (HBA1c >5.8 then IFG); Mitchell(d) (HBA1c >5.8 then IFG or OGTT); Mitchell(e) (HBA1c
?5.9 then IFG and OGTT and HBA1c) and Mitchell(f) (HBA1c >5.7 then IFG and OGTT and HBA1c)
https://doi.org/10.1371/journal.pone.0210674.t005
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disappointing in their ability to diagnose diabetes when used alone. OGTT (at�145 mg/dl)
had 50% PPV and HBA1c only 31.5%. As above, all tests performed better in a rule-out capac-
ity that excludes those without a diagnosis of diabetes with minimal false negatives. All tests
had NPVs above 90%, but the highest values were those related to the OGTT, fasting glucose
with HBA1c. When combined with their occurrence in patients without diabetes, the optimal
screening test was an adapted OGTT. Judging the overall performance by fraction/overall cor-
rect: OGTT was the optimal single test.
Single metabolic tests (a priori thresholds). Using conventional cut-offs in HBA1c by
definition produced a correct confirmation of diabetes. In addition, all produced excellent
rule-out statistics with few false negatives, suitable for use as an initial screening step. However,
only 2hr OGTT can be seriously considered for case-finding newly defined diabetes in those
taking antipsychotic medication. Here, although an OGTT >199 would define diabetes (100%
PPV), such a result would only occur in 57% of people with diabetes. HBA1c was unsatisfac-
tory as a method of confirming newly redefined diabetes, as only 4 out of 10 patients with dia-
betes would score positive on HBA1c at a cut-point of 6.5% (48 mmol/mol).
Algorithm approaches. We investigated the same seven algorithm approaches to the
diagnosis of newly defined diabetes. The most accurate approach was an initial HBA1c fol-
lowed by conventional testing. The main question is what cut-off on HBA1c is optimal. At a
cut-off of�5.9 this protocol achieves 97.7% overall accuracy, and only requires OGTT and
fasting glucose in 25% of the sample, and at a cut-off of�5.7, this protocol achieves 98.5%
overall accuracy, and only requires OGTT and fasting glucose in 32.7% of the sample as
opposed to 100% testing of all three measures to achieve 100% accuracy. Its only limitation
was a slight loss in sensitivity to 85.2%. As the cut-off of�5.7 is also now recommended for
prediabetes, this is the one we would recommend in SMI.
Fig 4. ROC curve of metabolic measures vs new definition of diabetes.
https://doi.org/10.1371/journal.pone.0210674.g004
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Discussion
Diabetes is increasingly recognised as important in patients with SMI. Observational studies
have reported a clear association between patients with established severe mental illness and
diabetes [8, 44, 45]. The risk appears particularly severe in those maintained on antipsychotic
drugs, notably most atypical antipsychotics although risk is elevated in those older conven-
tional antipsychotics [46, 47]. A series of meta-analyses have documented that the rate of dia-
betes is high in those with chronic schizophrenia (12.8%; N = 9; n = 2142; 39.3±9.4 yrs),
bipolar disorder (9.0%; N = 4; n = 1118; 42.1±8.5 yrs) and depression (7.6%; N = 6; n = 2827;
47.1±7.6 yrs) [48, 49, 50]. Pre-diabetes defined by impaired fasting glucose > 100mg/dl was
also high in schizophrenia (24.2%) bipolar disorder (17.3%) and depression (17.6%). In short,
all those with SMI appear to have a high risk of pre-diabetes and diabetes. This is particularly
the case for those maintained on long-term atypical antipsychotic medication [44]. There is
therefore a great need to identify and treat glucose dysregulation in patients on typical and
non-atypical antipsychotics. Unfortunately it is also clear that the implementation of screening
for diabetes and metabolic components is inconsistent [51, 52]. Even after the launch of many
national guidelines on physical healthcare monitoring, blood glucose is only tested in about
half of patients under psychiatric care [43]. Rates of metabolic surveillance appear to be signifi-
cantly lower for patients with SMI than for patients with known diabetes [53, 54]. Indeed bio-
chemical tests are often inadequately collected in patients with SMI. This may be particularly
the case for patients in prison, in long-stay facilities, those seen in primary care and also those
seen at home and in general medical hospital settings [55]. Yet, non-invasive clinical tests are
often more frequently offered. A recent meta-analysis showed that 75% of patients with SMI
on antipsychotic medication received assessment of body weight. Whilst 75% is still less than
ideal, many clinicians consider measurement of clinical variables as practical and measurable
in busy settings but would consider measurement of biochemical variables impractical.
This is the first study to examine whether clinical variables can be used to identify patients
at high risk of diabetes in mental health settings. None of the clinical variables: gender, age,
mental health global assessment of function (GAF), mental health clinicians’ global impression
(CGI), duration of severe mental illness, height, weight, BMI, waist/hip ratio were completely
satisfactory and none could be used instead of conventional biochemical testing. Where bio-
chemical testing is considered impractical or inconvenient (or perhaps when facilities are not
available) BMI or waist/hip ratio could be used as an approximate initial screen in order to
rule-out those at low risk. A BMI less than 30 would correctly identify non-diabetic patients
with SMI with about 92.5% accuracy (NPV), that is, with a 7.5% false negative rate. BMI could
not be used to confirm the presence of diabetes because of its low PPV (21.3%). Given the high
rates of not just diabetes, but also pre-diabetes in SMI, there may be some merit in screening
for pre-diabetes and diabetes combined. If the BMI was used to identify not just diabetes but
pre-diabetes and diabetes, then the PPV would increase from 21% to 65.2% but NPV would
fall to from 92.5% to 58.5%. Thus performance of the optimal clinical variable (BMI) would
remain unsatisfactory even if pre-diabetes was the target. This means that basing judgments
about diabetes (or pre-diabetes) upon single clinical factors cannot be recommended.
The next question we addressed is whether a combination of clinical variables can be used
to identify patients at high risk of diabetes in mental health settings. Previous studies appear to
suggest that combination models may improve upon the accuracy offered by individual clini-
cal variables alone. Based on the published literature regarding the performance of clinical
models in the general population (Table 1) we chose to examine the Leicester Practice Risk
Score (LPRS) and the Topics Diabetes Risk Score (TDRS) in patients with SMI. In large scale
population studies the LPRS achieved an area under the curve 0.72 and a Youden score of
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0.239.30 The TDRS achieved an area under the curve of 0.77 and a Youden score of 0.408 [31].
In this study, we found very similar results. Here the LPRS achieved an area under the curve
0.756 and a Youden score of 0.383. The TDRS achieved an area under the curve of 0.765 and
Youden score of 0.388. Thus the performance of these models was almost identical to their
own validation cohorts and indeed the recommended cut points were the same on ROC curve
testing. Yet in practical terms, neither could be used to reliably confirm diabetes. A negative
TDRS (a score of<8) was potentially useful in that the TDRS had 95.4% negative predictive
value (yielding 5% false negatives) but the TDRS would only be negative (under threshold) in
67% of non-diabetic SMI patients. Further when looking for at risk patients (with either pre-
diabetes or diabetes) their performance was further reduced. Overall then the clinical predic-
tion models appear to have little if any advantage over the individual clinical variables used
alone.
The prompt detection of diabetes is a priority in patients with SMI but we find little to sup-
port the routine use of clinical variables in order to accurately identify those with diabetes (or
indeed at risk with prediabetes). It is possible that clinical risk factors of importance were not
measured in this study and the future risk profiling may prove beneficial. For example several
models incorporated diet and fitness, not measured in this study. In this study age, BMI, waist/
hip ratio and illness duration were associated with diabetes and could be incorporated infor-
mally by clinicians concerned about risk of diabetes in order to focus advice or resources.
However, no clinical variables were a satisfactory proxy for a diagnosis of diabetes and as such
we recommend conventional biochemical testing for patients with SMI where diabetes or pre-
diabetes is a potential concern.
Regarding biochemical predictors, we found that a single application of HBA1c and other
markers of glucose regulation should be used with caution in patients with SMI taking antipsy-
chotics. Repeat testing (after several weeks) using the HBA1c would likely improve accuracy
but this has not been formally studied even in the general population [56]. Since this study was
conducted before the introduction of 2010 guidelines we could not precisely replicate the 2010
recommendations. Nevertheless results of this large prospective observation study demon-
strate that in settings using the older definition of diabetes, the two-hour OGTT is the optimal
single test at a cut point of 199 mg/dL, but this is not perfect, as reliance on this one test would
miss 25.8% of diabetic cases. At an a-priori cut of 199 mg/dL (7.0mol/L), there was excellent
rule-out ability, but a reduced performance for case-finding diabetes, simply because one in
four people with diabetes have a normal OGTT, but abnormal fasting glucose. However, reli-
ance on IFG (at a cut point of>125 mg/dL) would miss 51.6% of people with diabetes and reli-
ance on HBA1c (at a cut point of�6.5% (48 mmol/mol)) would miss 72.6% of people with
diabetes. This means that the gold standard of a fasting glucose and an OGTT cannot be
replaced by a single test if optimal accuracy is required. Regarding metabolic tests for the
newly proposed definition of diabetes, the same limitations apply. Conventional OGTT, IFG
and HBA1c miss 43.2%, 67% and 55.6% people with diabetes respectively when used alone.
HBA1c is sometimes proposed as a single one-off test of diabetes in some centres. We have
shown this is not recommended at the conventional cut-point of�6.5% (48 mmol/mol) in this
population due to its poor sensitivity. Only about 4 in 10 patients with diabetes score at 6.5%
(48 mmol/mol) or above. In clinical practice, this would result in the majority of people with
diabetes patients being missed if this were the only test used. HbA1c is generally less sensitive
than IFG and OGTT in diagnosing diabetes in those with mild disease [8].
We found that HBA1c can be used as an initial screening step in a diagnostic algorithm
(Fig 5). An algorithm consisting of HBA1c�5.7% followed by both FG and OGTT was the
optimal test that did not require all patients to have HBA1c, OGTT and FG. It is important to
note that modification of the cut-point to 5.7% improves sensitivity from 44.4% to up to 85%.
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A higher cut-point of�5.9% could be chosen, but at the penalty of loss in sensitivity. At
�5.7% only one in three people would need to have fasting and challenge test. Therefore, in
psychiatric settings, for patients with SMI taking antipsychotics we recommend a modification
of the cut-point to�5.7% as defined by the newly defined World Health Organisation/Ameri-
can Diabetes Association standard [57] when looking for diabetes. We believe these results are
generalisable to most organizations treating patients with antipsychotic medication. An
HBA1c cut-point of�5.7% is identical to the one found using ROC analyses of the US
NHANES data (�5.7%) as the best combination of sensitivity (39%) and specificity (91%) to
identify pre-diabetes [58]. HBA1c�5.7% was subsequently adopted internationally as the
threshold to diagnose prediabetes. Several previous studies measured HBA1c in patients with
SMI taking antipsychotics. Krein et al (2006) found mean HbA1c to be lower among those
with versus those without SMI, although testing was not systematic in this study [59]. Brown
et al (2011) found that diabetic patients with SMI had lower HbA1c levels than those without
SMI [60]. In this context, second-generation antipsychotics appear to adversely influence
HBA1c levels [61].
Recommendations for application of a diagnostic test for diabetes
Taking results together we suggest the following approach. All patients with SMI taking anti-
psychotic medications at initiation of the drug should be tested using HBA1c�5.7%. If nega-
tive, the test should be repeated again in 6 months. If positive, proceed to step 2, immediately
(but certainly within 2 weeks) obtain and use HBA1c and fasting glucose and OGTT at con-
ventional cuts-offs. If testing is done immediately, HBA1c does not need to be repeated, as
those scoring�6.5% (48 mmol/mol) are already apparent. OGTT and FG can be obtained at
the same time, minimizing patient burden. Repeat testing with more than a single test is in
accordance with national recommendations for the diagnosis of diabetes in asymptomatic
Fig 5. Optimal protocol for testing diabetes in SMI.
https://doi.org/10.1371/journal.pone.0210674.g005
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patients [3, 48]. These recommend repeat testing for all patients with an abnormal initial test,
except for those in a hyperglycemic crisis or classic symptoms of hyperglycemia and a random
plasma glucose�200 mg/dL. They also recommend that it is preferable that the same test be
repeated (at a later date) for confirmation. The value of repeat testing at two points in time on
the same patients has not yet been studied in patients taking antipsychotics. In our opinion, all
patients taking antipsychotics should be routinely tested for diabetes and prediabetes due to
the high risk and adverse consequences. Currently, recommendations for routine testing for
diabetes in asymptomatic, undiagnosed adults include adults of any age with BMI�25 kg/m2
and one or more of the known risk factors for diabetes [53]. We suggest that patients with SMI
taking antipsychotic medication is added to the list of known diabetic risk factors.
It is important that once diabetes is detected, that timely and appropriate treatment is
given. In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, 38% of
those with detected diabetes at baseline were left untreated [62]. Mitchell et al (2010) reviewed
eleven studies that compared the quality of diabetes care in patients with and without mental
illness in routine clinical settings and found significant disparities [63]. Mai et al (2012) studied
quality of diabetes care in 139,208 people with mental illness and 294,180 matched controls
from Western Australia [64]. Patients had lower rates of screenings (HbA1c, blood lipids), but
increased risks of hospitalization for diabetes complications including diabetes-related
mortality.
However, it is important to note some considerations when interpreting our results. We
did not have prospective data on how pre-diabetes or diabetes might change in this sample.
We did not have data on repeat testing which could be examined as a possible diagnostic strat-
egy. One important factor is that we did not have data on end organ dysfunction which is an
important and adverse outcome from diabetes. Future research should seek to ascertain this
information.
In conclusion, patients with SMI taking antipsychotics are at significantly increased risk of
diabetes and, therefore, clinicians must be vigilant for symptoms of diabetes, diabetic risk fac-
tors and also screen at regular intervals (we recommend annually). In order to best identify
newly redefined diabetes, we recommend a simple biochemical algorithm as follows: step 1.
HBA1c�5.7%; if negative, test again in 6 months, but if step 1 is positive, proceed to conven-
tional testing (HBA1c and fasting glucose and OGTT at conventional cuts-offs). Patients with
diabetes should be referred to an appropriate specialist and at the same time have a review by
mental health specialist to clarify which risk factors, including prescription of potentially haz-
ardous antipsychotic medication can be addressed. Such recommendations may be improved
by improved integrated and collaborative care between physical and mental healthcare
facilities.
Supporting information
S1 File. Full data set.
(XLS)
Author Contributions
Data curation: Martien Wampers, Ruud van Winkel, Weiping Yu, Marc De Hert.
Formal analysis: Alex J. Mitchell, Davy Vancampfort, Peter Manu.
Visualization: Davy Vancampfort, Christoph U. Correll, Marc De Hert.
An observational study diabetes screening in seriously mental ill patients receiving antipsychotic medication
PLOS ONE | https://doi.org/10.1371/journal.pone.0210674 September 12, 2019 19 / 23
Writing – original draft: Alex J. Mitchell, Davy Vancampfort, Peter Manu, Christoph U. Cor-
rell, Martien Wampers, Ruud van Winkel, Weiping Yu, Marc De Hert.
Writing – review & editing: Alex J. Mitchell, Peter Manu.
References
1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. Global Burden of Metabolic
Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global
trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis oaf health
examination surveys and epidemiological studies with 370 country-years and 2�7 million participants.
Lancet. 2011; 378(9785):31–40. https://doi.org/10.1016/S0140-6736(11)60679-X PMID: 21705069
2. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Dia-
betes Federation, 2017. http://www.diabetesatlas.org
3. American Diabetes Association Standards of Medical Care in Diabetes—2010 Diabetes Care. 2010;
33(Supplement_1): S11–S61.
4. American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2016;
39Suppl 1:S13–22.
5. Selvin E, Steffes MW, Zhu H et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondia-
betic adults.N Engl J Med 2010; 362:800–811 https://doi.org/10.1056/NEJMoa0908359 PMID:
20200384
6. Zhang X, Gregg EW, Williamson DF et al. A1C level and future risk of diabetes: a systematic review.
Diabetes Care 2010; 33:1665–167 https://doi.org/10.2337/dc09-1939 PMID: 20587727
7. van’t Riet E, Alssema M, Rijkelijkhuizen JM et al. Relationship between A1c and glucose levels in the
general Dutch population. Diabetes Care 2010; 33: 61–66. https://doi.org/10.2337/dc09-0677 PMID:
19808928
8. Karnchanasorn R1, Huang J2, Ou HY3, Feng W2, Chuang LM4, Chiu KC2, et al. Comparison of the
Current Diagnostic Criterion of HbA1c with Fasting and 2-Hour Plasma Glucose Concentration.J Diabe-
tes Res. 2016:6195494. https://doi.org/10.1155/2016/6195494 PMID: 27597979
9. Mostafa SA, Davies MJ, Webb D, Gray LJ, Srinivasan BT, Jarvis J, et al. The potential impact of using
glycated haemoglobin as the preferred diagnostic tool for detecting Type 2 diabetes mellitus.Diabet
Med. 2010; 27(7):762–9. https://doi.org/10.1111/j.1464-5491.2010.03015.x PMID: 20636956
10. Cohen D., Stolk R.P., Grobbee D.E., Gispen-de Wied C.C. Hyperglycemia and diabetes in patients with
schizophrenia or schizoaffective disorders.Diabetes care 2006; 29 (4), 786–791. PMID: 16567816
11. De Hert M, Dekker J.M., Wood D., Kahl K.G., Holt R.I.G., Mo¨ller H.-J. Cardiovascular disease and dia-
betes in people with severe mental illness position statement from the European Psychiatric Association
(EPA), supported by the European Association for the Study of Diabetes (EASD) and the European
Society of Cardiology (ESC) Eur Psychiatry. 2009; 24(6):412–24. https://doi.org/10.1016/j.eurpsy.
2009.01.005 PMID: 19682863
12. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabe-
tes? A critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry 2006; 18:183–194.
PMID: 16923657
13. Galling B1, Rolda´n A2, Nielsen RE3, Nielsen J4, Gerhard T5, Carbon M1, et al. Type 2 Diabetes Melli-
tus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis. JAMA Psychiatry.
2016 Mar; 73(3):247–59. https://doi.org/10.1001/jamapsychiatry.2015.2923 PMID: 26792761
14. De Hert M, Hanssens L, Wampers M, et al. Prevalence and incidence rates of metabolic abnormalities
and diabetes in a prospective study of patients treated with second-generation antipsychotics. Schi-
zophr Bull 2007; 33:560.
15. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome
and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first epi-
sode, untreated and treated patients.Schizophr Bull. 2012. [Epub ahead of print]
16. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new
onset diabetes, within 3 months after initiation or switch to atypical antipsychotic medication in patients
with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008; 69:472–479. PMID: 18348593
17. Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms
of action. CNS Drugs. 2011 1; 25(12):1035–59.
18. Correll CU, Kane JM, Manu P. Identification of high-risk coronary heart disease patients receiving atypi-
cal antipsychotics: Single low-density lipoprotein cholesterol threshold or complex national standard? J
Clin Psychiatry 2008; 69:578–583. PMID: 18370572
An observational study diabetes screening in seriously mental ill patients receiving antipsychotic medication
PLOS ONE | https://doi.org/10.1371/journal.pone.0210674 September 12, 2019 20 / 23
19. De Hert M, Van Eyck D, Hanssens L, Peuskens H, Thys E, Wampers M, et al. Oral glucose tolerance
tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines
for monitoring of patients on second generation antipsychotics?Eur Psychiatry. 2006; 21(4):224–6.
PMID: 16139484
20. van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Screening for diabe-
tes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evalu-
ation of incidence and screening methods. J Clin Psychiatry. 2006; 67(10):1493–500. PMID: 17107239
21. Manu P, Correll CU, van Winkel R, Wampers M, DeHert M. Prediabetes in patients treated with antipsy-
chotic drugs. J Clin Psychiatry. 2012; 73(4):460–6. https://doi.org/10.4088/JCP.10m06822 PMID:
22225552
22. Agarwal SK. Prediabetes in a schizophrenia population. European Psychiatry 2012, 27 (suppl 1)P-
1198
23. Hanssens L, De Hert M, Van Eyck D, Wampers M, Peuskens J, Scheen A. Usefulness of Glycated hae-
moglobin (HbA1c) to screen for diabetes in patients with schizophrenia Schizophrenia Research 2006;.
85, iss. 1–3: 296–297. PMID: 16690257
24. Paulweber B, Valensi P, Lindstrom J, Lalic NM, Greaves CJ, McKee M, et al. A European evidence-
based guideline for the prevention of type 2 diabetes.HormMetab Res 2010; 42(suppl 1):S3–36.
25. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes pre-
vention. Diabet Med 2007; 24:451–63 PMID: 17470191
26. Schwarz PE, Li J, Lindstrom J, Tuomilehto J. Tools for predicting the risk of type 2 diabetes in daily prac-
tice. 2009. HormMetab Res 41: 86–97
27. Collins GS, Mallett S, Omar O, Yu LM. Developing risk prediction models for type 2 diabetes: a system-
atic review of methodology and reporting. BMC Med. 2011; 9:103. https://doi.org/10.1186/1741-7015-
9-103 PMID: 21902820
28. Buijsse B, Simmons RK, Griffin SJ, Schulze MB. Risk assessment tools for identifying individuals at risk
of developing type 2 diabetes. Epidemiol Rev 2011; 33:46–62 https://doi.org/10.1093/epirev/mxq019
PMID: 21622851
29. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: sys-
tematic review. BMJ 2011; 343:d7163 https://doi.org/10.1136/bmj.d7163 PMID: 22123912
30. Abbasi A, Peelen LM, Corpeleijn E, et al. Prediction models for risk of developing type 2 diabetes: sys-
tematic literature search and independent external validation study BMJ Open. 2012; 345: e5900.
31. Brown N, Critchley N, Bogowicz P, et al. Risk scores based on self-reported or available clinical data to
detect undiagnosed Type 2 Diabetes: A systematic review Diabetes Research and Clinical Practice
2012 in press.
32. Heikes KE, Eddy DM, Arondekar B, Schlessinger L. Diabetes Risk Calculator: a simple tool for detecting
undiagnosed diabetes and pre-diabetes. Diabetes Care. 2008; 31(5):1040–1045 PMID: 18070993
33. Gray LJ, Taub NA, Khunti K, Gardiner E, Hiles S, Webb DR, et al. The Leicester Risk Assessment
score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multieth-
nicUK setting. Diabet Med. 2010; 27(8):887–95. https://doi.org/10.1111/j.1464-5491.2010.03037.x
PMID: 20653746
34. Heianza Y, Arase Y, Saito K, Hsieh SD, Tsuji H, Kodama S, et al. Development of a Screening Score
for Undiagnosed Diabetes and Its Application in Estimating Absolute Risk of Future Type 2 Diabetes in
Japan: Toranomon Hospital Health Management Center Study 10 (TOPICS 10). J
ClinEndocrinolMetab.2013
35. Lindstro¨m J, Absetz P, Hemio K et al. Reducing the risk of type 2 diabetes with nutrition and physical
activity—efficacy and implementation of lifestyle interventions in Finland. Public Health Nutr 2010; 13
(6A):993–9 https://doi.org/10.1017/S1368980010000960 PMID: 20513271
36. Aleksandra Gilis-Januszewska A, Szybinski Z, Kissimova-Skarbek K et al. Prevention of type 2 diabe-
tes by lifestyle intervention in primary health care setting in Poland: Diabetes in Europe Prevention
using Lifestyle, physical Activity and Nutritional intervention (DE-PLAN) project. British Journal of Dia-
betes & Vascular Disease 2011; 11:4 198–203
37. Costa B, Barrio F, Cabre´ JJ, Piñol JL, Cos X, Sole´ C, et al; DE-PLAN-CAT Research Group. Delaying
progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary health-
care settings using intensive lifestyle intervention. Diabetologia. 2012; 55(5):1319–28. https://doi.org/
10.1007/s00125-012-2492-6 PMID: 22322921
38. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model
assessment: insulin resistance and and beta-cell function from fasting plsma glucose and insulin con-
centration in man. Diabetologia 1985; 28:412–419. PMID: 3899825
An observational study diabetes screening in seriously mental ill patients receiving antipsychotic medication
PLOS ONE | https://doi.org/10.1371/journal.pone.0210674 September 12, 2019 21 / 23
39. Aas IH. Guidelines for rating Global Assessment of Functioning (GAF). Arch Gen Psychiatry 2011; 20;
10:2.
40. Rabinowitz J, Mehnert A, Eerdekens M. To what extent do the PANSS and CGI-S overlap? J ClinPsy-
chopharmacol 2006; 26:303–307.
41. Mitchell AJ. The clinical significance of subjective memory complaints in the diagnosis of mild cognitive
impairment and dementia: a meta-analysis. Int J Geriatr Psychiatry. 2008; 23(11): 1191–1202 https://
doi.org/10.1002/gps.2053 PMID: 18500688
42. Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination in the detection of
dementia and mild cognitive impairment. J Psychiatr Res. 2009; 43(4):411–31. https://doi.org/10.1016/
j.jpsychires.2008.04.014 PMID: 18579155
43. Mitchell AJ. Sensitivity × PPV is a recognized test called the clinical utility index (CUI+). Eur J Epidemiol.
2011; 26(3):251–2 https://doi.org/10.1007/s10654-011-9561-x PMID: 21442261
44. Gianfrancesco F, Pesa J, Wang RH, et al. Assessment of anti psychotic-related risk of diabetes mellitus
in a Medicaid psychosis population: Sensitivity to study design. American Journal Of Health-System
Pharmacy 2006; Volume: 63 Issue: 5 Pages: 431–441 PMID: 16484517
45. Smith M; Hopkins D; Peveler RC, et al. First- V. second-generation antipsychotics and risk for diabetes
in schizophrenia: systematic review and meta-analysis. British Journal Of Psychiatry 2008; 192 Issue:
6 Pages: 406–411 https://doi.org/10.1192/bjp.bp.107.037184 PMID: 18515889
46. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabe-
tes? A critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry 2006; 18:183–194.
PMID: 16923657
47. Rajkumar AP1, Horsdal HT1, Wimberley T1, Cohen D1, Mors O1, Børglum AD1, et al. Endogenous
and Antipsychotic-Related Risks for Diabetes Mellitus in Young People with Schizophrenia: A Danish
Population-Based Cohort Study. Am J Psychiatry. 2017 1; 174(7):686–694 https://doi.org/10.1176/
appi.ajp.2016.16040442 PMID: 28103712
48. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syn-
drome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and
meta-analysis. Schizophr Bull. 2013; 39(2):306–18. https://doi.org/10.1093/schbul/sbr148 PMID:
22207632
49. Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, et al. Metabolic syn-
drome and metabolic abnormalities in bipolar disorder: A meta-analysis of prevalence rates and moder-
ators. Am J psychiatry 2013; https://doi.org/10.1176/appi.ajp.2012.12050620
50. Vancampfort D, Correll CU, Wampers M, Sienaert P, Mitchell AJ, De Herdt A, et al. Metabolic syndrome
and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences
and moderating variables. Psychol Med. 2014; 44(10):2017–28. https://doi.org/10.1017/
S0033291713002778 PMID: 24262678
51. De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, et al. Guidelines for screen-
ing and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry.
2011; 199(2):99–105. https://doi.org/10.1192/bjp.bp.110.084665 PMID: 21804146
52. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of met-
abolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of
screening practices. Psychol Med. 2012; 42(1):125–47. https://doi.org/10.1017/S003329171100105X
PMID: 21846426
53. Hardy S, Hinks P, Gray R. Screening for cardiovascular risk in patients with severe mental illness in pri-
mary care: A comparison with patients with diabetes. J Ment Health. 2013; 22(1):42–50. https://doi.org/
10.3109/09638237.2012.759194 PMID: 23343046
54. Mitchell AJ, Hardy S. Surveillance for metabolic risk factors in patients with severe mental illness vs dia-
betes: National Comparison of Screening Practices. Psychiatric Services 2013 in press
55. Osborn DP, Baio G, Walters K, Petersen I, Limburg H, Raine R, et al. Inequalities in the provision of car-
diovascular screening to people with severe mental illnesses in primary care: cohort study in the United
Kingdom THIN Primary Care Database 2000–2007. Schizophr Res. 2011; 129(2–3):104–10. https://
doi.org/10.1016/j.schres.2011.04.003 PMID: 21550783
56. Owora AH1.Commentary: Diagnostic Validity and Clinical Utility of HbA1c Tests for Type 2 Diabetes
Mellitus.Curr Diabetes Rev. 2018; 14(2):196–199. https://doi.org/10.2174/
1573399812666161129154559 PMID: 27897108
57. American Diabetes Association.Standards of medical care in diabetes—2012.Diabetes Care. 2012;
35Suppl 1:S11–63.
58. American Diabetes A. Standards of medical care in diabetes 2011. Diabetes Care 2011; 34 (suppl 1):
S11–61.
An observational study diabetes screening in seriously mental ill patients receiving antipsychotic medication
PLOS ONE | https://doi.org/10.1371/journal.pone.0210674 September 12, 2019 22 / 23
59. Krein SL, Bingham CR, McCarthy JF, Mitchinson A, Payes J, Valenstein M. Diabetes treatment among
VA patients with comorbid serious mental illness. Psychiatr Serv. 2006; 57:1016Y1021.
60. Brown CH, Medoff D, Dickerson FB, Kreyenbuhl JA, Goldberg RW, Fang L, et al. Long-term glucose
control among type 2 diabetes patients with and without serious mental illness. J NervMent Dis. 2011;;
199(11):899–902.
61. Castilla-Puentes R. Effects of psychotropics on Glycated hemoglobin (HbA1c) in a cohort of bipolar
patients. Bipolar Disord. 2007; 9(7):772–8. PMID: 17988369
62. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and dia-
betes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res
2006; 86:15–22. PMID: 16884895
63. Mitchell AJ, Malone D, Doebbeling CC. Quality of medical care for people with and without comorbid
mental illness and substance misuse: systematic review of comparative studies. Br J Psychiatry. 2009;
194(6):491–9. https://doi.org/10.1192/bjp.bp.107.045732 PMID: 19478286
64. Mai Q, D’Arcy C, Holman J, Sanfilippo FM, Emery JD, Preen DB. Mental illness related disparities in
diabetes prevalence, quality of care and outcomes: a population-based longitudinal study. BMC Medi-
cine 2011; 9:118 https://doi.org/10.1186/1741-7015-9-118 PMID: 22044777
65. Aekplakorn W, Bunnag P, Woodward M, Sritara P, Cheepudomwit S, Yamwong S, et al: A risk score for
predicting incident diabetes in the Thai population. Diabetes Care 2006; 29:1872–1877. PMID:
16873795
66. Balkau B, Lange C, Fezeu L, Tichet J, de Lauzon-Guillain B, Czernichow S, et al. Predicting diabetes:
clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resis-
tance Syndrome (DESIR). Diabetes Care 2008; 31:2056–2061. https://doi.org/10.2337/dc08-0368
PMID: 18689695
67. Gao WG, Qiao Q, Pitka¨niemi J, Wild S, Magliano D, Shaw J, et al. Risk prediction models for the devel-
opment of diabetes in Mauritian Indians. Diabet Med 2009; 16:996–1002.
68. Kahn HS, Cheng YJ, Thompson TJ, Imperatore G, Gregg EW. Two risk-scoring systems for predicting
incident diabetes mellitus in U.S. adults age 45 to 64 years. Ann Intern Med 2009; 150:741–751 PMID:
19487709
69. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabe-
tes Care 2003; 26:725–31. PMID: 12610029
70. Robinson CA, Agarwal G, Nerenberg K. Validating the CAN-RISK prognostic model for assessing dia-
betes risk in Canada’s multi-ethnic population. Chronic Dis Inj Can 2011; 32:19–31 PMID: 22153173
71. Schulze M, Hoffman K, Boeing H, Linseisen J, Rohrmann S, Mohlig M, et al. An accurate risk score
based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes.
Diabetes Care 2007; 30:510–5. PMID: 17327313
72. Al-Lawati JA, Tuomilehto J. Diabetes risk score in Oman: a tool to identify prevalent type 2 diabetes
among Arabs of the Middle East. Diabetes Res ClinPract 2007; 77:438–44.
73. Baan CA, Ruige JB, Stolk RP, Witteman JCM, Dekker JM, Heine RJ, et al. Performance of a predictive
model to identify undiagnosed diabetes in a health care setting. Diabetes Care 1999; 22:213–219.
PMID: 10333936
74. Bang H, Edwards A, Bomback A, Ballantyne C, Brillon D, Callahan M, et al. Development and validation
of a patient self-assessment score for diabetes risk. Ann Intern Med 2009; 151:775–83. https://doi.org/
10.7326/0003-4819-151-11-200912010-00005 PMID: 19949143
75. Gao WG, Dong YH, Pang ZC, Nan HR, Wang SJ, Ren J, et al: A simple Chinese risk score for undiag-
nosed diabetes. Diabet Med 2010; 27:274–281. https://doi.org/10.1111/j.1464-5491.2010.02943.x
PMID: 20536489
76. Glu¨mer C, Carstensen B, Sabdbaek A, Lauritzen T, Jørgensen T, Borch-Johnsen K: A Danish diabetes
risk score for targeted screening. Diabetes Care 2004; 27:727–733. PMID: 14988293
77. Pires de Sousa AG, Pereira AC, Marquezine GF, Marques do Nascimento-Neto R, Freitas SN, Nicolato
RLdC, et al. Derivation and external validation of a simple prediction model for the diagnosis of type 2
diabetes mellitus in the Brazilian urban population. Eur J Epidemiol 2009; 24:101–109. https://doi.org/
10.1007/s10654-009-9314-2 PMID: 19190989
78. Ramachandran A, Snehalatha C, Vijay V, Wareham N, Colagiuri S. Derivation and validation of diabe-
tes risk score for urban Asian Indians. Diabetes Res ClinPract 2005; 70:63–70.
An observational study diabetes screening in seriously mental ill patients receiving antipsychotic medication
PLOS ONE | https://doi.org/10.1371/journal.pone.0210674 September 12, 2019 23 / 23
